Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorde: A 6-week placebo-controlled trial

Neuropsychopharmacology

Volumn 20, Issue 5, 1999, Pages 491-505

  Daniel, David G ^a   Zimbroff, Dan L ^b   Potkin, Steven G ^c   Reeves, Karen R ^d   Harrigan, Edmund P ^d   Lakshminarayanan, Mani ^d  

^a Clinical Studies Ltd   (United States)

^b LOMA LINDA UNIVERSITY HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antipsychotic; Depression; Negative symptoms; Schizophrenia; Tolerability; Ziprasidone

Indexed keywords

NEUROLEPTIC AGENT; PLACEBO; ZIPRASIDONE;

ABDOMINAL PAIN; ADULT; AGED; AGITATION; AKATHISIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHIZOIDISM; SCHIZOPHRENIA; SOMNOLENCE; VERTIGO; VOMITING; XEROSTOMIA;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THIAZOLES;

EID: 0033136622     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00090-6     Document Type: Article

References (59)

1. American Psychiatric Association (1987): Diagnostic and statistical manual of mental disorders, 3rd edition, revised, APA, Washington, DC.
2. Barnes T.R.E. A rating scale for drug-induced akathisia. Br J Psych. 154:1989;672-682.
3. Barnes T.R.E., Curson D.A., Liddle P.F., Patel M. The nature and prevalence of depression in chronic schizophrenic inpatients. Br J Psychiatry. 154:1989;486-491.
4. Bartels S.J., Drake R.E. Depressive symptoms in schizophrenia. Comprehensive differential diagnosis Compr Psychiatry. 29:1988;467-483.
5. Beasley C.M., Satterlee W., Sanger T., Tollefson G., Tran P., Hamilton S. Olanzapine versus placebo. Results of a double-blind, fixed-dose olanzapine trial Psychopharmacology. 124:1996;159-167.
6. 11C-raclopride Psychopharmacology. 112:1993;308-314.
7. 2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography. Psychopharmacology. 124:1996;141-147.
8. Briley M., Moret C. Neurobiological mechanisms involved in antidepressant therapies. Clin Neuropharmacol. 16:1993;387-400.
9. 2 antagonist ziprasidone on drug-disrupted prepulse inhibition in the rat. Soc Neurosci Abstr 23:1953.
10. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P.W. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 14:1996;87-96.
11. Casey D.E. Side-effect profiles of new antipsychotic agents. J Clin Psychiatry. 57:1996;40-45.
12. Casey DE, Keepers GA (1988): Neuroleptic side effects: Acute extrapyramidal syndromes and tardive dyskinesia. In Psychopharmacology: Current Trends. Berlin: Springer, pp 74-93.
13. Deutch A.Y., Moghaddam B., Innis R.B., Krystal J.H., Aghajanian G.K., Bunney B.S., Charney D.S. Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia. Schiz Res. 4:1991;124-156.
14. Drake R.E., Gates C., Whitaker A., Cotton P.G. Suicide among schizophrenics. Compr Psychiat. 26:1985;90-100.
15. 18F]setoperone in healthy volunteers. Eur Neuropsychopharmacol. 6:1996;177.
16. Goff D.C., Posever T., Herz L., Simmons J., Kletti N., Lapierre K., Wilner K.D., Law G.C., Ko G.N. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 18(4):1998;296-304.
17. Janiszewski J.S., Fouda H.G., Cole R.O. Development and validation of a high-sensitivity assay for an antipsychotic agent, CP-88,059, with solid-phase extraction and narrow-bore high-performance liquid chromatography. J Chromatog. 668:1995;133-139.
18. Johnson D.A.W. Studies of depressive symptoms in schizophrenia. Br J Psychiat. 139:1981;89-101.
19. Kay S.R., Opler L.A., Lindenmeyer J.P. The positive and negative syndrome scale (PANSS). Rationale and standardization Br J Psychiat. 155:1989;59-65.
20. Keck P., Buffenstein A., Ferguson J., Feighner J., Jaffe W., Harrigan E.P., Ziprasidone Study Group Ziprasidone 40 mg/day and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder. A 4-week placebo-controlled trial Psychopharmacology. 140(2):1998;173-184.
21. Keepers G.A., Clappison V.J., Casey D.E. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiat. 40:1983;1113-1117.
22. Knights A., Hirsch S.R. Revealed depression and drug treatment for schizophrenia. Arch Gen Psychiat. 38:1981;806-811.
23. Koreen A.R., Siris S.G., Chakos M., Alvir J., Mayerhoff D., Lieberman J. Depression in first-episode schizophrenia. Am J Psychiat. 160:1993;1643-1648.
24. Kramer M.S., Vogel W.H., DiJohnson C., Dewey D.A., Sheves P., Cavicchia S., Little P., Schmidt R., Kimes I. Antidepressants in "depressed" schizophrenic inpatients. A controlled trial. Arch Gen Psychiat. 46:1989;922-928.
25. Lindenmeyer J.-P., Grochowski S., Kay S.R. Schizophrenic patients with depression. Psychopathological profiles and relationship with negative symptoms Compr Psychiat. 32:1991;528-533.
26. Lu Y, Zorn SH, Rollema H (1997): Comparison of the novel antipsychotic ziprasidone with clozapine: Effects on dopamine release in rat prefrontal cortex and dorsolateral striatum. Soc Neurosci Abstr 23:1931.
27. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am J Psychiat. 151:1994;825-835.
28. Martin R.L., Cloninger C.R., Guze S.B., Clayton P.J. Frequency and differential diagnosis of depressive syndromes in schizophrenia. J Clin Psychiat. 46:1985;9-13.
29. 2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J Pharmacol Exp Ther. 265:1993;498-508.
30. Mauri M.C., Bravin S., Fabiano L., Vanni S., Boscati L., Invernizzi G. Depressive symptoms and schizophrenia. A psychopharmacological approach L'Encéphale. 21:1995;555-558.
31. McGlashan T.H., Carpenter W.T. Postpsychotic depression in schizophrenia. Arch Gen Psychiat. 33:1976;231-239.
32. Meltzer H.Y. Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci. 3:1995;64-75.
33. Meltzer H.Y., Shigero M., Lee J.C. The ratios of serotonin 2 and dopamine 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull. 25:1989;390-392.
34. Metropolitan Life Insurance Company (1993): Height and Weight Standards.
35. Meyer M.C., Baldessarini R.J., Goff D.C., Centorrino F. Clinically significant interactions of psychotropic agents. Drug Saf. 15:1996;333-346.
36. Möller H.J. Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties. Eur Neuropsychopharmacol. 3:1993;1-11.
37. Möller H.J., Van Praag H., Aufdembrinke B., Working Group on Negative Symptoms in Schizophrenia Negative symptoms in schizophrenia. Considerations for clinical trials: Working Group on Negative Symptoms in Schizophrenia Psychopharmacology. 115:1994;221-228.
38. Montgomery S., Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiat. 134:1979;382-389.
39. Moore N.A., Calligaro D.O., Wong D.T., Bymaster F., Tye N.C. The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Investiga Drugs. 24:1993;281-293.
40. National Institutes of Mental Health (1976a): Clinical Global Impression Improvement Scale. In Guy W (ed), ECDEU Assessment Manual for Psychopharmacology.
41. National Institutes of Mental Health (1976b): Clinical Global Impression Severity Scale. In Guy W (ed), ECDEU Assessment Manual for Psychopharmacology.
42. National Institutes of Mental Health (1976c): Abnormal Movement Scale. In Guy W (ed), ECDEU Assessment Manual for Psychopharmacology.
43. Neal-Beliveau B.S., Joyce J.N., Lucki I. Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther. 265:1993;201-217.
44. 1A receptors. Neuropharmacology. 35:1996;119-121.
45. Niemegeers C.J.E., Janssen P.A.J. A systematic study of the pharmacological activities of dopamine antagonists. Life Sci. 24:1979;2201-2215.
46. Ortiz A., Gershon S. The future of neuroleptic psychopharmacology. J Clin Psychiat. 47:1986;3-11.
47. Pfeiffer W., Kockott G., Fischl B., Schleuning G. Adverse effects of long-term psychopharmacologic therapy on sexual functions. Psychiatrische Praxis. 18:1991;92-98.
48. 1A mechanism. Soc Neurosci Abstr 23:1931.
49. Rickels K., Schweizer E. The treatment of generalized anxiety disorder in patients with depressive symptomology. J Clin Psychiat. 54:1993;20-22.
50. Schotte A., Janssen P.F.M., Gommeren W., Luyten W.H.M.L., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs. In vitro and in vivo receptor binding Psychopharmacology. 124:1996;57-73.
51. Seeger T.F., Seymour P.A., Schmidt A.W., Zorn S.H., Schulz D.W., Lebel L.A., McLean S., Guanowsky V., Howard H.R., Lowe J.A., Heym J. Ziprasidone (CP-88,059). A new antipsychotic with combined dopamine and serotonin receptor antagonist activity J Pharmacol Exp Ther. 275:1995;101-113.
52. Seeman P., van Tol H.H.M. Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg. 6:1993;602-608.
53. 1A receptor system. Possible implications for schizophrenic negative symptomatology Psychiat Anns. 26:1996;88-92.
54. Silverstone T., Smith G., Goodall E. Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiat. 153:1988;214-217.
55. Simpson G.M., Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiat Scand. 212:1970;11-19.
56. 2 receptors. J Pharmacol Exp Ther. 266:1993;1375-1384.
57. Tandon R., Harrington E., Zorn S.H. Ziprasidone. a novel antipsychotic with unique pharmacology and therapeutic potential J Serotonin Research. 4:1997;159-177.
58. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiat. 31:1974;67-72.
59. Young J.L., Zonana H.V., Shepler L. Medication noncompliance in schizophrenia. Codification and update Bull Am Acad Psychiat Law. 14:1986;105-122.